

## PRESS RELEASE

**innate** pharma

---

### **HALF-YEAR REPORT ON INNATE PHARMA'S LIQUIDITY CONTRACT WITH GILBERT DUPONT**

**Marseilles, France, July 2, 2013**

---

Under the liquidity contract entrusted by Innate Pharma to Gilbert Dupont, the following assets appeared on the liquidity account as at June 30, 2013:


- 75,277 shares of Innate Pharma, and
- 184,719.98 euros in cash.

For information, the following assets appeared on the liquidity account at the latest report in December 2012:

- 86,829 shares of Innate Pharma, and
- 150,918.73 euros in cash.

At the implementation of the liquidity contract, on September 18, 2009, the following assets appeared on the liquidity account:

- 0 share of Innate Pharma, and
- 300,000.00 euros in cash.



## PRESS RELEASE

**innate** pharma

---

### About Innate Pharma:

Innate Pharma S.A. is a biopharmaceutical company developing first-in-class immunotherapy drugs for cancer and inflammatory diseases.

The Company specializes in the development of new monoclonal antibodies targeting receptors and pathways controlling the activation of innate immunity cells. Its innovative approaches have led to licensing agreements with Novo Nordisk A/S and Bristol-Myers Squibb.

Incorporated in 1999 and listed on NYSE-Euronext in Paris in 2006, Innate Pharma is based in Marseilles, France, and had 83 employees as at March 31, 2013.

Learn more about Innate Pharma at [www.innate-pharma.com](http://www.innate-pharma.com).

### Practical Information about Innate Pharma shares:

**ISIN code** FR0010331421  
**Ticker code** IPH

### Disclaimer:

This press release contains certain forward-looking statements. Although the company believes its expectations are based on reasonable assumptions, these forward-looking statements are subject to numerous risks and uncertainties, which could cause actual results to differ materially from those anticipated. For a discussion of risks and uncertainties which could cause the company's actual results, financial condition, performance or achievements to differ from those contained in the forward-looking statements, please refer to the Risk Factors ("Facteurs de Risque") section of the *Document de Reference* prospectus filed with the AMF, which is available on the AMF website (<http://www.amf-france.org>) or on Innate Pharma's website.

This press release and the information contained herein do not constitute an offer to sell or a solicitation of an offer to buy or subscribe to shares in Innate Pharma in any country.

### For additional information, please contact:

#### **Innate Pharma**

Laure-Hélène Mercier  
Director, Investor Relations  
Phone: +33 (0)4 30 30 30 87  
[investors@innate-pharma.com](mailto:investors@innate-pharma.com)

#### **ATCG Press**

Marielle Bricman  
Mob.: +33 (0)6 26 94 18 53  
[mb@atcg-partners.com](mailto:mb@atcg-partners.com)